New immediate release formulation for deterring abuse of methadone

Pharmaceutical Development and Technology

Volumn 18, Issue 2, 2013, Pages 535-543

  Betancourt, A O ^a   Gosselin, P M ^a   Vinson, R K ^b  

^a Pharmaceutical Research and Development   (Canada)

^b Product Development   (Canada)

Author keywords

Alkaline agents; Dissolution; Drug abuse; Opioids; Tablets

Indexed keywords

ALCOHOL; MEGLUMINE; METHADONE; WATER;

ARTICLE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; IMMEDIATE RELEASE FORMULATION; IN VITRO STUDY; PRIORITY JOURNAL; ROOM TEMPERATURE; SOLVENT EXTRACTION; TABLET FORMULATION; TABLET MANUFACTURE;

CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; ETHANOL; METHADONE; SOLUBILITY; SOLUTIONS; TABLETS; WATER;

EID: 84862007041     PISSN: 10837450     EISSN: 10979867     Source Type: Journal    
DOI: 10.3109/10837450.2012.680598     Document Type: Article

References (16)

1. FDA, Guidance for Industry. Assessment of Abuse Potential of Drugs (DRAFT GUIDANCE). Guidance document distributed for comment purposes only, Rockville, MD, 2010
2. Katz N. Abuse-deterrent opioid formulations: Are they a pipe dream? Curr Rheumatol Rep 2008;10:11-18
3. Webster L. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. Pain Med 2009;10 Suppl 2: S124-S133
4. Shaw IF, Berk J. Orally administered drug composition for therapy in the treatment of narcotic drug addiction. US patent 3, 980,766. 1976
5. Kumar V, Dixon D, Tewari D, Wadgaonkar D. Method and compositions for deterring abuse of opioid containing dosage forms. US Patent Application US 2007/0264327, 2007
6. Raffa RB, Pergolizzi JV Jr. Opioid formulations designed to resist/deter abuse. Drugs 2010;70:1657-1675
7. Vaghefi F, Liversidge GG, Ruddy SB, Cooper ER. Abuse-resistant pharmaceutical compositions. US Patent Application US 2006/2006
8. Andersen C, Jespersen L. Egalet® morphine, a once-a-day, abuse resistant opioid analgesics: A double-blind, randomized, crossover efficacy study in cancer patients. Available at: Http://www. egalet.com/multimedia/ Morphine-PhaseII-Poster-final-2009-04-29.pdf
9. Haahr AM, Lyhne-Iversen L, Ridderberg S, Nilsson M, Hemmingsen P. Drug abuse resistant, controlled release, using Egalet® dosage units. CRS Poster. 2006; 680
10. Kaiko RF, Colucci RD. Opioid agonist/antagonist combinations. US Patent 6, 277, 384. 2001
11. US Pharmacopeia (USP 33-NF 28). 2011
12. FDA, Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms. Rockville, MD, U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER), 1997
13. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Guideline Q 1 A (R2): Stability testing of new drug substances and products. Geneva, Switzerland, International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use, 2003 The Merck Index, 10th Ed., editor M., Windholz, Rathway, N.J.: Merck &Co., Inc., 1983
14. Benson DW, Kaufman JJ, Koski WS. Theoretic significance of pH dependence of narcotics and narcotic antagonists in clinical anesthesia. Anesth Analg 1976;55:253-256
15. Rowe RC, Sheskey PJ, Owen SC, eds. Handbook of pharmaceutical excipients. 5th ed., 2006
16. Inactive Ingredient Search for Approved Drug Products. Database Last Updated: January 19, 2012.Available at: Http://www. accessdata.fda.gov/scripts/ cder/iig/getiigWEB.cfm